Scott has more than 30 years of commercial leadership experience across the pharmaceutical industry. He currently serves as a Venture Advisor at Vida Ventures and as an Advisor to Google Ventures. Prior to this, he was the Chief Executive Officer at PACT Pharma, Inc., a clinical-stage privately held biopharmaceutical company. Mr. Garland also served as President and Chief Executive Officer of Portola Pharmaceuticals Inc., where he successfully led the company through development, commercialization and ultimately through its acquisition by Alexion Pharmaceuticals, Inc.
Earlier in his career, Mr. Garland served as Chief Commercial Officer at Relypsa, Inc. and Exelixis, Inc. He has also held numerous commercial leadership and sales and marketing positions at Genentech, Inc., Amgen Inc., and Merck & Co., Inc. Mr. Garland was responsible for the launch or marketing of many important therapeutics, including Avastin and Rituxan.
In addition to Enliven, he currently serves on the boards of directors of LB Pharmaceuticals Inc., Day One Biopharmaceuticals, Inc., Olema Pharmaceuticals, Inc., and ALX Oncology Holdings Inc.
Scott holds an M.B.A from Duke University’s Fuqua School of Business and a B.A. from California Polytechnic University (San Luis Obispo).
How do I contact J. Scott Garland?
Has J. Scott Garland been buying or selling shares of Enliven Therapeutics?
Who are Enliven Therapeutics' active insiders?
Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Mika Derynck (Director), J. Scott Garland (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Lori Kunkel (Director), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?
In the last twelve months, insiders at the sold shares 26 times. They sold a total of 523,044 shares worth more than $20,039,774.98. The most recent insider tranaction occured on October, 1st when Director
J. Scott Garland sold 13,000 shares worth more than $606,710.00. Insiders at Enliven Therapeutics own 3.0% of the company.
Learn More about insider trades at Enliven Therapeutics. Information on this page was last updated on 10/1/2026.
